The Current Ratio as of November 2024 (TTM) for Lyra Therapeutics, Inc. (LYRA) is 3.64

According to Lyra Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.64. This represents a change of -16.15% compared to the average of 4.34 of the last 4 quarters.

Lyra Therapeutics, Inc. (LYRA) Historical Current Ratio (quarterly & annually)

How has LYRA Current Ratio performed in the past?

The mean historical Current Ratio of Lyra Therapeutics, Inc. over the last ten years is 7.52. The current 3.64 Current Ratio has changed 4.74% with respect to the historical average. Over the past ten years (40 quarters), LYRA's Current Ratio was at its highest in in the June 2020 quarter at 22.66. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Lyra Therapeutics, Inc. (LYRA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Lyra Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lyra Therapeutics, Inc. (LYRA) Average Current Ratio

How has LYRA Current Ratio performed in the past?

The current Current Ratio of Lyra Therapeutics, Inc. (LYRA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Lyra Therapeutics, Inc. (LYRA) Current Ratio vs. Peers

How is LYRA’s Current Ratio compared to its peers?

Lyra Therapeutics, Inc.’s Current Ratio is greater than CytomX Therapeutics, Inc. (1.04), greater than Assembly Biosciences, Inc. (2.36), less than Achilles Therapeutics plc (6.04), less than Neoleukin Therapeutics, Inc. (15.33), less than Instil Bio, Inc. (12.90), less than NextCure, Inc. (9.07), greater than Spero Therapeutics, Inc. (2.68), less than Nuvation Bio Inc. (9.57), less than Cullinan Oncology, Inc. (24.46), greater than Bolt Biotherapeutics, Inc. (3.16), less than Day One Biopharmaceuticals, Inc. (14.62), less than Autolus Therapeutics plc (13.69),

Build a custom stock screener for Lyra Therapeutics, Inc. (LYRA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lyra Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lyra Therapeutics, Inc. (LYRA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lyra Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.